{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:35:53Z","timestamp":1789050953742,"version":"build-2803163510"},"reference-count":161,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud University Nijmegen Medical Centre","doi-asserted-by":"publisher","award":["RvB21.52264"],"award-info":[{"award-number":["RvB21.52264"]}],"id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) is a hematologic neoplasm characterized by the expression of the BCR::ABL1 oncoprotein, a constitutively active tyrosine kinase, resulting in uncontrolled growth and proliferation of cells in the myeloid lineage. Targeted therapy using tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, bosutinib, ponatinib and asciminib has drastically improved the life expectancy of CML patients. However, treatment resistance occurs in 10\u201320% of CML patients, which is a multifactorial problem that is only partially clarified by the presence of TKI inactivating BCR::ABL1 mutations. It may also be a consequence of a reduction in cytosolic TKI concentrations in the target cells due to transporter-mediated cellular distribution. This review focuses on drug-transporting proteins in stem cells and progenitor cells involved in the distribution of TKIs approved for the treatment of CML. Special attention will be given to ATP-binding cassette transporters expressed in lysosomes, which may facilitate the extracytosolic sequestration of these compounds.<\/jats:p>","DOI":"10.3390\/pharmaceutics15112535","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T06:20:16Z","timestamp":1698301216000},"page":"2535","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9322-5468","authenticated-orcid":false,"given":"Noor E.","family":"Verhagen","sequence":"first","affiliation":[{"name":"Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan B.","family":"Koenderink","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1801-2072","authenticated-orcid":false,"given":"Nicole M. A.","family":"Blijlevens","sequence":"additional","affiliation":[{"name":"Department of Haematology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. W. M.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-2314","authenticated-orcid":false,"given":"Frans G. M.","family":"Russel","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev.biochem.69.1.373","article-title":"Protein tyrosine kinase structure and function","volume":"69","author":"Hubbard","year":"2000","journal-title":"Annu. Rev. Biochem."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Baykal-K\u00f6se, S., Acikgoz, E., Yavuz, A.S., G\u00f6n\u00fcl Geyik, \u00d6., Ate\u015f, H., Sezerman, O.U., \u00d6zsan, G.H., and Y\u00fcce, Z. (2020). Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229104"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Amarante-Mendes, G.P., Rana, A., Datoguia, T.S., Hamerschlak, N., and Brumatti, G. (2022). BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010215"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2003.10.007","article-title":"Molecular mechanisms of resistance of leukemia to imatinib mesylate","volume":"28","author":"Tauchi","year":"2004","journal-title":"Leuk. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety","volume":"9","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.2021014689","article-title":"Asciminib: A new therapeutic option in chronic-phase CML with treatment failure","volume":"139","author":"Yeung","year":"2022","journal-title":"Blood"},{"key":"ref_12","first-page":"7787","article-title":"Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence","volume":"25","author":"Ciftciler","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.tips.2016.08.003","article-title":"Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors","volume":"37","author":"Neul","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010611-134529","article-title":"Drug Transporters in Drug Efficacy and Toxicity","volume":"52","author":"DeGorter","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2012.10.015","article-title":"Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy","volume":"68","author":"Angelini","year":"2013","journal-title":"Pharmacol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.114.097451","article-title":"Lysosomal Sequestration Determines Intracellular Imatinib Levels","volume":"88","author":"Burger","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1242\/dev.124.10.1929","article-title":"Identification of a lineage of multipotent hematopoietic progenitors","volume":"124","author":"Morrison","year":"1997","journal-title":"Development"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1073\/pnas.94.10.5320","article-title":"Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice","volume":"94","author":"Bhatia","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: Stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: Similarities, differences and clinical prospects in CML and AML","volume":"20","author":"Vetrie","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat. Med."},{"key":"ref_30","first-page":"3951","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Kantarjian","year":"2009","journal-title":"Cancer Control"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Alves, R., Gon\u00e7alves, A.C., Rutella, S., Almeida, A.M., De Las Rivas, J., Trougakos, I.P., and Sarmento Ribeiro, A.B. (2021). Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia\u2014From Molecular Mechanisms to Clinical Relevance. Cancers, 13.","DOI":"10.3390\/cancers13194820"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood.2022018196","article-title":"Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells","volume":"142","author":"Qiu","year":"2023","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: Current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1634\/stemcells.2005-0066","article-title":"Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells","volume":"23","author":"Soucek","year":"2005","journal-title":"Stem Cells"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/bdd.598","article-title":"In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1","volume":"29","author":"Rochat","year":"2008","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: A review","volume":"477","author":"Kumar","year":"2022","journal-title":"Mol. Cell. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1\u2013mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2009-05-222471","article-title":"Properties of CD34+ CML stem\/progenitor cells that correlate with different clinical responses to imatinib mesylate","volume":"116","author":"Jiang","year":"2010","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.exphem.2006.01.020","article-title":"Selective expression of cholesterol metabolism genes in normal CD34+CD38\u2212 cells with a heterogeneous expression pattern in AML cells","volume":"34","author":"Peeters","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(91)90141-K","article-title":"Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells","volume":"66","author":"Chaudhary","year":"1991","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","article-title":"Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells","volume":"21","author":"Brendel","year":"2007","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"576559","DOI":"10.3389\/fonc.2020.576559","article-title":"P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers","volume":"10","author":"Seelig","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2014An update","volume":"17","author":"Mao","year":"2015","journal-title":"Aaps J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.critrevonc.2007.02.003","article-title":"ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance","volume":"62","author":"Kuipers","year":"2007","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2016.179","article-title":"The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment","volume":"31","author":"Eadie","year":"2017","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cyto.10157","article-title":"Single-cell image analysis to assess ABC-transporter-mediated efflux in highly purified hematopoietic progenitors","volume":"49","author":"Raaijmakers","year":"2002","journal-title":"Cytometry"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Eadie, L.N., Hughes, T.P., and White, D.L. (2016). ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161470"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V99.2.507","article-title":"The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors","volume":"99","author":"Scharenberg","year":"2002","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.leu.2404131","article-title":"Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38\u2212 cells","volume":"20","author":"Raaijmakers","year":"2006","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fendo.2019.00204","article-title":"The Roles of Cholesterol and Its Metabolites in Normal and Malignant Hematopoiesis","volume":"10","author":"Oguro","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00109-021-02088-w","article-title":"Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer","volume":"99","author":"Tabassum","year":"2021","journal-title":"J. Mol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Paterson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/ijc.24868","article-title":"Cancer stem\/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma","volume":"126","author":"Zhu","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","article-title":"Development of imatinib and dasatinib resistance: Dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1","volume":"52","author":"Gromicho","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Kitai, K., Kawaguchi, K., Tomohiro, T., Morita, M., So, T., and Imanaka, T. (2021). The lysosomal protein ABCD4 can transport vitamin B(12) across liposomal membranes in vitro. J. Biol. Chem., 296.","DOI":"10.1016\/j.jbc.2021.100654"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/bloodadvances.2021006040","article-title":"Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: An ALFA-ELAM02 joint study","volume":"6","author":"Ceraulo","year":"2022","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tang, L., Bergevoet, S.M., Gilissen, C., de Witte, T., Jansen, J.H., van der Reijden, B.A., and Raymakers, R.A.P. (2010). Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells. BMC Pharmacol., 10.","DOI":"10.1186\/1471-2210-10-12"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"22811","DOI":"10.3390\/ijms160922811","article-title":"Pharmacogenetics of BCR\/ABL Inhibitors in Chronic Myeloid Leukemia","volume":"16","author":"Polillo","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s13238-015-0148-2","article-title":"The physiological role of drug transporters","volume":"6","author":"Liang","year":"2015","journal-title":"Protein Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biopha.2014.01.009","article-title":"Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients","volume":"68","author":"Au","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/0008-5472.CAN-08-3953","article-title":"Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations","volume":"69","author":"Seeliger","year":"2009","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2005.02.093","article-title":"KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors","volume":"23","author":"Sihto","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood.V97.8.2440","article-title":"ARG tyrosine kinase activity is inhibited by STI571","volume":"97","author":"Okuda","year":"2001","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.5045\/br.2023.2023017","article-title":"Asciminib: The first-in-class allosteric inhibitor of BCR::ABL1 kinase","volume":"58","author":"Choi","year":"2023","journal-title":"Blood Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/asheducation-2016.1.156","article-title":"Molecular monitoring in chronic myeloid leukemia-how low can you go?","volume":"2016","author":"Branford","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","article-title":"Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis","volume":"41","author":"Wojnicz","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/14737140.8.6.853","article-title":"Imatinib mesylate for the treatment of chronic myeloid leukemia","volume":"8","author":"Soverini","year":"2008","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000336610","article-title":"Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia","volume":"127","author":"Nardinelli","year":"2012","journal-title":"Acta Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"Deborah","year":"2012","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-1999","article-title":"Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)","volume":"20","author":"Nies","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1248\/bpb.b14-00254","article-title":"Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells","volume":"37","author":"Yamakawa","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","article-title":"Interaction of imatinib mesilate with human P-glycoprotein","volume":"307","author":"Hamada","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e23374","DOI":"10.1002\/jcla.23374","article-title":"Overexpression of P-glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients","volume":"34","author":"Ammar","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0925-4439(02)00095-9","article-title":"Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1","volume":"1587","author":"Sarkadi","year":"2002","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11095-007-9376-3","article-title":"Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells","volume":"25","author":"Hirayama","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2005-10-4020","article-title":"Complex interaction of BCRP\/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression","volume":"108","author":"Nakanishi","year":"2006","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","article-title":"The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients","volume":"65","author":"Breedveld","year":"2005","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1158\/1078-0432.CCR-06-1599","article-title":"The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2","volume":"13","author":"Liu","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/s41467-020-16155-2","article-title":"ABCG2 transports anticancer drugs via a closed-to-open switch","volume":"11","author":"Orlando","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"39068","DOI":"10.1074\/jbc.M306362200","article-title":"Akt signaling regulates side population cell phenotype via Bcrp1 translocation","volume":"278","author":"Mogi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.18388\/abp.2013_2014","article-title":"Role of anti-apoptotic pathways activated by BCR\/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors","volume":"60","author":"Danisz","year":"2013","journal-title":"Acta Biochim. Pol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2014.38","article-title":"The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia","volume":"28","author":"Giannoudis","year":"2014","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Eadie, L.N., Dang, P., Goyne, J.M., Hughes, T.P., and White, D.L. (2018). ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192180"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00441-016-2554-z","article-title":"The biology of the ABCA3 lipid transporter in lung health and disease","volume":"367","author":"Beers","year":"2017","journal-title":"Cell Tissue Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/bjh.12246","article-title":"Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance","volume":"161","author":"Hupfeld","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.bmcl.2004.09.042","article-title":"Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases","volume":"14","author":"Manley","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib","volume":"87","author":"Tanaka","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1515\/dmdi-2013-0062","article-title":"Role of OATP-1B1 and\/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors","volume":"29","author":"Khurana","year":"2014","journal-title":"Drug Metab. Drug Interact."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: Implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood.V110.11.2364.2364","article-title":"Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells","volume":"110","author":"Davies","year":"2007","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cbi.2017.06.012","article-title":"Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels","volume":"273","author":"Mlejnek","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","article-title":"Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters","volume":"78","author":"Tiwari","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2009.242","article-title":"Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: Implications for combination TKI therapy","volume":"24","author":"Hiwase","year":"2010","journal-title":"Leukemia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","article-title":"The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro","volume":"127","author":"Blake","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00228-015-1968-y","article-title":"Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia","volume":"72","author":"Ishida","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants","volume":"65","author":"Walters","year":"2005","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2008.103","article-title":"Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration","volume":"22","author":"Chapuy","year":"2008","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/oncolo\/oyab040","article-title":"FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial","volume":"27","author":"Pulte","year":"2022","journal-title":"Oncologist"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Musumeci, F., Greco, C., Grossi, G., Molinari, A., and Schenone, S. (2018). Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia. Cancers, 10.","DOI":"10.3390\/cancers10110430"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/leu.2015.35","article-title":"Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells","volume":"29","author":"Lu","year":"2015","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","article-title":"The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2","volume":"11","author":"Sen","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3892\/or.2014.3002","article-title":"Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells","volume":"31","author":"Sun","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_132","first-page":"375","article-title":"SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2133\/dmpk.DMPK-13-RG-126","article-title":"Population pharmacokinetic and pharmacodynamic analysis of bosutinib","volume":"29","author":"Hsyu","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial","volume":"36","author":"Cortes","year":"2022","journal-title":"Leukemia"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1038\/s41598-021-85757-7","article-title":"Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy","volume":"11","author":"Abumiya","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-015-0179-4","article-title":"In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib","volume":"8","author":"Redaelli","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.1019","article-title":"Pharmacokinetics of Asciminib When Taken With Imatinib or With Food","volume":"11","author":"Hoch","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_143","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 (T315I)-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"13423","DOI":"10.18632\/oncotarget.24393","article-title":"The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro","volume":"9","author":"Eadie","year":"2018","journal-title":"Oncotarget"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/13543784.2021.1941863","article-title":"Asciminib: An investigational agent for the treatment of chronic myeloid leukemia","volume":"30","author":"Breccia","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/dmd.112.050054","article-title":"Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)","volume":"41","author":"Kazmi","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"45117","DOI":"10.18632\/oncotarget.15155","article-title":"Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis","volume":"8","author":"Zhitomirsky","year":"2017","journal-title":"Oncotarget"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1002\/1873-3468.13967","article-title":"An inventory of lysosomal ABC transporters","volume":"594","author":"Szakacs","year":"2020","journal-title":"FEBS Lett."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3324\/haematol.2009.008631","article-title":"ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug","volume":"94","author":"Chapuy","year":"2009","journal-title":"Haematologica"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4155\/fmc-2019-0350","article-title":"The growing evidence for targeting P-glycoprotein in lysosomes to overcome resistance","volume":"12","author":"Stefan","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/sj.leu.2403853","article-title":"Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia","volume":"19","author":"Zong","year":"2005","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"672287","DOI":"10.3389\/fonc.2021.672287","article-title":"Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib","volume":"11","author":"Loscocco","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/jcpt.12197","article-title":"Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients","volume":"39","author":"Au","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Prado-Carrillo, O., Arenas-Ram\u00edrez, A., Llaguno-Munive, M., Jurado, R., P\u00e9rez-Rojas, J., Cervera-Ceballos, E., and Garcia-Lopez, P. (2022). Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147715"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Alves, R., Gon\u00e7alves, A.C., Jorge, J., Almeida, A.M., and Sarmento-Ribeiro, A.B. (2022). Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051158"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/15680096113139990076","article-title":"P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives","volume":"13","author":"Binkhathlan","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"643382","DOI":"10.3389\/fonc.2021.643382","article-title":"Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation","volume":"11","author":"Mu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/11\/2535\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:12:06Z","timestamp":1760130726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/11\/2535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":161,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["pharmaceutics15112535"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15112535","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}